Shattuck Labs director granted 81,000 stock options

Shattuck Labs director Helen M. Boudreau received a grant of stock options covering 81,000 shares of common stock.

Rhea-AI Filing Summary

Shattuck Labs director Helen M. Boudreau received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and give her the right to buy the shares in the future.

According to the terms, the 81,000 options will vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before Shattuck Labs’ next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 81,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 81,000 shares

Grant/Award 1 txn

Insider Boudreau Helen M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	81,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 81,000 contracts (Direct)

Footnotes (1)

1. F1. This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Option grant size: 81,000 options Exercise price: $5.95 per share Underlying shares: 81,000 shares +2 more

5 metrics

Option grant size 81,000 options Stock Option (Right to Buy) granted to director

Exercise price $5.95 per share Conversion or exercise price for the options

Underlying shares 81,000 shares Common Stock underlying the option grant

Post-transaction holdings 81,000 derivative securities Total options held directly after the grant

Option expiration date May 29, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.9500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Shattuck Labs (STTK) report for Helen M. Boudreau?

Shattuck Labs reported that director Helen M. Boudreau received a grant of stock options for 81,000 shares of common stock at an exercise price of $5.95 per share, as disclosed in a Form 4 insider transaction filing with the SEC.

How many Shattuck Labs (STTK) shares are covered by Helen Boudreau’s new options?

Helen Boudreau’s new option grant covers 81,000 shares of Shattuck Labs common stock. These options represent the right to purchase those shares if exercised in the future, subject to vesting and other terms described in the Form 4 filing.

What is the exercise price of Helen Boudreau’s Shattuck Labs (STTK) stock options?

The stock options granted to Helen Boudreau have an exercise price of $5.95 per share. This is the price she must pay per share to purchase Shattuck Labs common stock if she chooses to exercise the options after they vest.

When do Helen Boudreau’s Shattuck Labs (STTK) options vest?

Helen Boudreau’s options vest in full on the earlier of the one-year anniversary of the grant date or immediately before Shattuck Labs’ next annual meeting of stockholders, provided she continues serving the company through that date, according to the Form 4 footnote.

What is the expiration date of Helen Boudreau’s Shattuck Labs (STTK) stock options?

Helen Boudreau’s stock options expire on May 29, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Shattuck Labs common stock under this grant, as detailed in the Form 4 filing.

How many Shattuck Labs (STTK) derivative securities does Helen Boudreau hold after this grant?

Following this stock option grant, Helen Boudreau holds 81,000 derivative securities related to Shattuck Labs common stock. This figure represents the total options from this award reported as directly owned after the transaction on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudreau Helen M

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TEXAS 78701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.95	05/29/2026		A		81,000		(1)	05/29/2036	Common Stock	81,000	$0	81,000	D

Explanation of Responses:

1. This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

	/s/ Andrew R. Neill, Attorney-in-Fact for Helen M. Boudreau	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)